High HMGA2 expression without gene rearrangement in meningiomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• High mobility group AT-hook 2 (HMGA2) is a transcriptional regulator implicated in mesenchymal tumors.
• Aberrant HMGA2 expression and chromosomal rearrangements at 12q14 are noted in various mesenchymal tumors.
• Meningioma, a prevalent brain tumor of mesenchymal origin, warrants investigation into HMGA2's role.

Purpose of the Study:

• To analyze HMGA2 expression (full-length and truncated forms) in meningioma tissues.
• To investigate potential gene rearrangements involving HMGA2 at chromosomal region 12q14.
• To correlate HMGA2 expression with clinicopathological features and proliferation markers.

Main Methods:

• Analysis of 55 meningioma cases.
• Quantification of truncated and full-length HMGA2 expression.
• Fluorescence in situ hybridization (FISH) for gene rearrangements.
• 3'-rapid amplification of cDNA ends (3'-RACE) for transcript variants.
• Assessment of Ki-67 labeling index.

Main Results:

• 95% of meningiomas showed elevated HMGA2 expression compared to normal brain tissue.
• Truncated HMGA2 exceeded full-length HMGA2 expression by over two-fold in 14 cases.
• No chromosomal translocations involving 12q14 were detected.
• HMGA2 expression did not correlate with Ki-67 index or clinicopathological features.

Conclusions:

• Increased HMGA2 expression is a common finding in meningiomas, independent of 12q14 chromosomal rearrangements.
• The elevated HMGA2 expression in meningiomas is not associated with tumor cell proliferation.
• HMGA2's role in meningioma pathogenesis may differ from its role in other mesenchymal tumors.